Antigout Drug Raws Febuxostat CAS 144060-53-7 for Disease Treatment

Antigout Drug Raws Febuxostat CAS 144060-53-7 for Disease Treatment

Product Name: Febuxostat
Synonyms: FEBUXOSTAT;Tei-6720;2-[3-Cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid;2-[3-Cyano-4-isobutoxyphenyl]-4-methylthiazole-5-carboxylic acid;2-(3-Cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic Acid;2-[3-Cyano-4-(2-methylpropoxy)phenyl]-4-methyl-5-thiazolecarboxylic Acid;TMX 67;Febuxosta
CAS: 144060-53-7
MF: C16H16N2O3S
MW: 316.37

Febuxostat product description

Febuxostat developed by Teijin is a new generation of xanthine oxidase inhibitor, for the treatment of high uric acid disease (gout) on clinical , the structure is completely different from xanthine oxidase inhibitor drug developed 40 years ago, it is a new and efficient non-purine selective inhibitor of xanthine oxidase. Xanthine oxidase is a key enzyme in the promotion of uric acid. Febuxostat reduces blood uric acid level in gout patients with hyperuricemia , clinical studies show that the product is safe and effective, this product is metabolized by the liver, it does not depend on renal excretion, so for moderate - severe liver and kidney dysfunction patients it is not necessary to reduce the dose. Dose is once 1 day, 40 mg or 80 mg once ,it is not recommended for the treatment of gout patients without hyperuricemia.
In February 2009, the US Food and Drug Administration (FDA) approved febuxostat for long-term treatment of gout patients with hyperuricemia.

Febuxostat Usage And Synthesis

Uses Treatment of high uric acid disease (gout)

Chemical Properties Crystalline Solid

Usage antihyperlipidemic

Usage Xanthine oxidase/xanthine dehydrogenase inhibitor. Used for treatment of hyperuricemia and chronic gout. 40-120 mg/day febuxostat was proven effective in lowering serum urate levels when administered to manage hyperuricemia in patients with gout.

Usage Febuxostat is primarily indicated in conditions like Gout, Hyperuricemia

Febuxostat Anti-gout drug

Gout is a heterogeneous group of diseases, hereditary or acquired due to uric acid excretion decreasing and purine metabolism. Because the body produces too much uric acid and renal clearance capacity decreases, uric acid accumulates in the body, leading to urate crystals deposited in the joints and organs. Therefore, it means the treatment of gout usually taken to be: promote uric acid excretion, and suppression of uric acid, and adopt appropriate measures to improve related symptoms. 

Uric acid formation is associated with purine metabolism, in the final step of purine metabolism, hypoxanthine becomes xanthine through the role of xanthine oxidoreductase (XOR) ,then further generate uric acid ,inhibiting activity of the enzyme can effectively reduce uric acid production. Febuxostat is currently the world's latest generation of non-purine selective inhibitor of xanthine oxidase, which acts highly selectively on the oxidase, then reduces uric acid synthesis, reduces uric acid levels, thus effectively treats ventilation diseases. 

30 years, Allopurinol is the only clinically used drugs to inhibit production of uric acid and is used as gold drugs widely in clinical treatment of gout, and achieves good results in the anti-gout treatment. Compared with allopurinol, febuxostat has obvious advantages:

(1) allopurinol only inhibit reduced XOR while febuxostat shows a significant inhibitory effect on oxidized and reduced XOR , so its role of reducing the uric acid is more powerful, long-lasting;

(2) Because allopurinol is a purine analog,it is inevitable affecting other purine and pyridine metabolic activity . Therefore, allopurinol treatment should be repeated large doses of the drugs to maintain a high level. This also leads to serious or even fatal adverse reactions due to the accumulation of the drug-induced. However, Febuxostat as non-purine XOR inhibitors, has better security.